Type 2 Diabetes Control in a Nonobese Rat Model Using Sleeve Gastrectomy with Duodenal–Jejunal Bypass (SGDJB)
详细信息 查看全文
- 作者：Dong Sun (1)
Shaozhuang Liu (1)
Guangyong Zhang (1)
Weijie Chen (1)
Zhibo Yan (1)
Sanyuan Hu (1) - 关键词：Sleeve gastrectomy with duodenal–jejunal bypass ; Sleeve gastrectomy ; Bariatric surgery ; Ghrelin ; Goto–Kakizaki rat
- 刊名：Obesity Surgery
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：22
- 期：12
- 页码：1865-1873
- 全文大小：466KB
- 参考文献：1. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-3. CrossRef
2. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-0. discussion 350-. CrossRef
3. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-7. CrossRef
4. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-6. e5. CrossRef
5. Buchwald H, Oien DM. Metabolic/Bariatric Surgery Worldwide 2008. Obes Surg. 2009;19(12):1605-1. CrossRef
6. Boza C, Gagner M, Devaud N, et al. Laparoscopic sleeve gastrectomy with ileal transposition (SGIT): a new surgical procedure as effective as gastric bypass for weight control in a porcine model. Surg Endosc. 2008;22(4):1029-4. CrossRef
7. Alexander JW, Hawver LRM, Goodman HR. Banded sleeve gastrectomy—initial experience. Obes Surg. 2009;19(11):1591-. CrossRef
8. Aguirre V, Stylopoulos N, Grinbaum R, et al. An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity (Silver Spring). 2008;16(12):2585-2. CrossRef
9. del Genio G, Gagner M, Cuenca-Abente F, et al. Laparoscopic sleeve gastrectomy with duodeno-jejunal bypass: a new surgical procedure for weight control. Feasibility and safety study in a porcine model. Obes Surg. 2008;18(10):1263-. CrossRef
10. Kasama K, Tagaya N, Kanehira E, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass: technique and preliminary results. Obes Surg. 2009;19(10):1341-. CrossRef
11. Gan SS, Talbot ML, Jorgensen JO. Efficacy of surgery in the management of obesity-related type 2 diabetes mellitus. ANZ J Surg. 2007;77(11):958-2. CrossRef
12. Pereferrer FS, Gonzalez MH, Rovira AF, et al. Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal implications. Obes Surg. 2008;18(1):97-08. CrossRef
13. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-. CrossRef
14. Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes—a new perspective for an old disease. Ann Surg. 2004;239(1):1-1. CrossRef
15. Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-4 kg/m(2): a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195-. CrossRef
16. Ramos AC, Galvao Neto MP, de Souza YM, et al. Laparoscopic duodenal–jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI <30 kg/m2 (LBMI). Obes Surg. 2009;19(3):307-2. CrossRef
17. Praveen Raj P, Kumaravel R, Chandramaliteeswaran C, et al. Is laparoscopic duodenojejunal bypass with sleeve an effective alternative to roux en y gastric bypass in morbidly obese patients: preliminary results of a randomized trial. Obes Surg. 2012;22(3):422-. CrossRef
18. Navarrete SA, Leyba JL, Llopis SN. Laparoscopic sleeve gastrectomy with duodenojejunal bypass for the treatment of type 2 diabetes in non-obese patients: technique and preliminary results. Obes Surg. 2011;21(5):663-. CrossRef
19. Gagner M. Laparoscopic sleeve gastrectomy with duodenojejunal bypass for severe obesity and/or type 2 diabetes may not require duodenojejunal bypass initially. Obes Surg. 2010;20(9):1323-. CrossRef
20. de Bona Castelan J, Bettiol J, d’Acampora AJ, et al. Sleeve gastrectomy model in Wistar rats. Obes Surg. 2007;17(7):957-1. CrossRef
21. Schlager A, Khalaileh A, Mintz Y, et al. A mouse model for sleeve gastrectomy: applications for diabetes research. Microsurgery. 2011;31(1):66-1. CrossRef
22. Li F, Zhang G, Liang J, et al. Sleeve gastrectomy provides a better control of diabetes by decreasing ghrelin in the diabetic Goto–Kakizaki rats. J Gastrointest Surg. 2009;13(12):2302-. CrossRef
23. Mattews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-. CrossRef
24. Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477-4.
25. Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes—a systematic review. Diabetes Metab Res Rev. 2004;20(6):438-5. CrossRef
26. Tice JA, Karliner L, Walsh J, et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008;121(10):885-3. CrossRef
27. Karra E, Yousseif A, Batterham RL. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab. 2010;21(6):337-4. CrossRef
28. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252(6):966-1. CrossRef
29. Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin—a hormone with multiple functions. Front Neuroendocrinol. 2004;25(1):27-8. CrossRef
30. Peng Z, Xiaolei Z, Al-Sanaban H, et al. Ghrelin inhibits insulin release by regulating the expression of inwardly rectifying potassium channel 6.2 in islets. Am J Med Sci. 2012;343(3):215-. CrossRef
31. Tymitz K, Engel A, McDonough S, et al. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg. 2011;21(1):125-0. CrossRef
32. Bohdjalian A, Langer FB, Shakeri-Leidenmuehler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535-0. CrossRef
33. Rao RS, Kini S. GIP and bariatric surgery. Obes Surg. 2011;21(2):244-2. CrossRef
34. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005;288(2):E447-3. CrossRef
35. Pacheco D, Antonio de Luis D, Romero A, et al. The effects of duodenal–jejunal exclusion on hormonal regulation of glucose metabolism in Goto–Kakizaki rats. Am J Surg. 2007;194(2):221-. CrossRef
36. Wang TT, Hu SY, Gao HD, et al. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg. 2008;247(6):968-5. CrossRef
37. Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008;18(8):574-. CrossRef
38. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-06. CrossRef
39. Lee HC, Kim MK, Kwon HS, et al. Early changes in incretin secretion after laparoscopic duodenal–jejunal bypass surgery in type 2 diabetic patients. Obes Surg. 2010;20(11):1530-. CrossRef
40. Basso N, Capoccia D, Rizzello M, et al. First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surg Endosc. 2011;25(11):3540-0. CrossRef
41. Masuda T, Ohta M, Hirashita T, et al. A comparative study of gastric banding and sleeve gastrectomy in an obese diabetic rat model. Obes Surg. 2011;21(11):1774-0. CrossRef
42. Strader AD, Clausen TR, Goodin SZ, et al. Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg. 2009;19(1):96-04. CrossRef
43. Chelikani PK, Shah IH, Taqi E, et al. Comparison of the effects of Roux-en-Y gastric bypass and ileal transposition surgeries on food intake, body weight, and circulating peptide YY concentrations in rats. Obes Surg. 2010;20(9):1281-. CrossRef
44. De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10-0. CrossRef
45. Chelikani PK, Haver AC, Reeve JR, et al. Daily, intermittent intravenous infusion of peptide YY(3-6) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol. 2006;290(2):R298-05. CrossRef
46. Sileno AP, Brandt GC, Spann BM, et al. Lower mean weight after 14 days intravenous administration peptide YY3-6 (PYY3-6) in rabbits. Int J Obes (Lond). 2006;30(1):68-2. CrossRef
47. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-6) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol. 2007;293(1):R39-6. CrossRef
48. Reidelberger RD, Haver AC, Chelikani PK, et al. Effects of different intermittent peptide YY (3-6) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(2):R449-8. CrossRef
49. Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes Obes Metab. 2011;13(5):408-7. CrossRef
50. van den Hoek AM, Heijboer AC, Voshol PJ, et al. Chronic PYY3-6 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab. 2007;292(1):E238-5. CrossRef - 作者单位：Dong Sun (1)
Shaozhuang Liu (1)
Guangyong Zhang (1)
Weijie Chen (1)
Zhibo Yan (1)
Sanyuan Hu (1)
1. Department of General Surgery, Qilu Hospital of Shandong University, #107 Wenhua Xi Road, Jinan, 250012, Shandong, People’s Republic of China
文摘
Background As a new bariatric procedure, sleeve gastrectomy with duodenal–jejunal bypass (SGDJB) needs further assessment. We compared the diabetic control between SGDJB and sleeve gastrectomy (SG) in Goto–Kakizaki (GK) rats, a nonobese rat model of type 2 diabetes. Our aim is firstly to develop a nonobese diabetic rat model for SGDJB and secondly to investigate the feasibility and safety of SGDJB to induce diabetes remission. Methods Fifty 11-week-old male GK rats were divided into five groups: sham-operated SG (SOSG), sham-operated SGDJB (SOSGDJB), control, SG, and SGDJB. Rats were observed for 16?weeks after surgery. The body weight, food intake, glycemic control outcomes, ghrelin, peptide YY (PYY), insulin, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic peptide were measured. Results The operated groups showed lower food intake since 4?weeks postoperation and significant weight loss since 6?weeks postoperation. SGDJB and SG surgeries induced a decreased fasting ghrelin level and increased levels of glucose-stimulated insulin, GLP-1, and PYY secretion at 2 and 16?weeks postoperation. Compared with the SG group, the SGDJB group showed higher glucose-stimulated GLP-1 levels. Both SGDJB and SG groups exhibited significant improvement in oral glucose tolerance and insulin tolerance compared with sham-operated and control groups, but there was no difference between the operated groups. Conclusions This nonobese diabetic rat model may be valuable in studying the effect of SGDJB on diabetic control. SGDJB shows similar improvement of glucose metabolism with SG. Our findings do not provide evidence for the foregut-mediated amelioration in glucose homeostasis.